The M&A hunt is on — here are the prime targets

Companies with advanced molecular therapies, oncology assets and obesity treatments could be fuel for a dealmaking fire this year.

By Kelly Bilodeau • Jan. 17, 2023

Focusing on smaller biotechs to have a big impact on society

Marcus Delatte discusses how and why he focuses his expertise on counseling smaller companies and mentoring the next generation of technical experts.

Jan. 17, 2023

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

How biotechs can weather the market storm

Execs at JPM sound off on moves companies can make to survive the challenging market conditions.

By Meagan Parrish • Jan. 13, 2023

Biopharma M&A may get the push it needs in 2023, but with a face lift

A flurry of recent deals has reinforced forecasts that the long drought is over — circumstances have changed though, and M&A may not be the same.

By Michael Gibney • Jan. 12, 2023

Space — the next frontier in drug development

Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.

By Kelly Bilodeau • Jan. 12, 2023

Galecto has identified a master switch to reduce fibroid formation

With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.

By Taren Grom • Jan. 11, 2023

Woman of the Week: Form Bio’s Claire Aldridge

The chief strategy officer of Form Bio is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.

By Taren Grom • Jan. 11, 2023

C-suite changes at Biogen, Bluebird, Novavax give insight into 2023 business plans

A breakdown of the most buzzworthy executive changes so far in the new year and how they’re causing ripples in the life sciences industry.

By Karissa Waddick • Jan. 10, 2023

Chinook Therapeutics nears the finish line in kidney disease

A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.

By Michael Gibney • Jan. 10, 2023

Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck

The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.

By Taren Grom • Jan. 9, 2023

What’s top of mind for industry execs at JPM?

Leaders in the space reveal the topics that are top of mind as the year’s biggest healthcare conference kicks off next week.

By Taren Grom • Jan. 6, 2023

Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023

As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.

By Michael Gibney • Jan. 5, 2023

Woman of the Week: Cambrian BioPharma’s Juliette Han

The CFO and COO is advancing moonshot efforts to address aging-related diseases for the "healthspan" company and is helping emerging biotechs bring innovations out of academia.

By Taren Grom • Jan. 4, 2023

Nonprofits are bridging R&D’s valley of death

How charitable firms such as Advancium are helping to right the market wrongs of drug development.

By Kelly Bilodeau • Jan. 4, 2023

The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences

A preview of the top trends on the minds of industry and market leaders for the new year.

By Taren Grom • Jan. 3, 2023

Beer, dolphins and more discoveries that could shed light on Alzheimer’s disease

New Alzheimer's drugs are poised to change the market — and in preclinical arenas, researchers are learning more and more about the disease.

By Michael Gibney • Dec. 22, 2022

Woman of the Week: Exelixis’ Dr. Vicki Goodman

With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.

By Taren Grom • Dec. 14, 2022

The 2023 PharmaVoice Year in Preview

Here’s a look at how industry leaders are navigating the key issues of 2023.

Dec. 12, 2022

With FDA filing on the horizon, Karuna appoints new CEO

Allergan alum Bill Meury will take the helm as current CEO Steve Paul transitions to lead R&D.

By Karissa Waddick • Dec. 9, 2022

For Duchenne-focused Sarepta, gene therapy is the natural next step

The company with three marketed RNA drugs for Duchenne muscular dystrophy is taking the logical leap into gene therapies with a candidate under review at the FDA.

By Michael Gibney • Dec. 8, 2022

Woman of the Week: Simcha Therapeutics’ Beatrice McQueen

From sea sponges to cytokines, the chief operating officer’s career has come full circle as she pursues a new approach to treating cancer via the immune system.

By Taren Grom • Dec. 7, 2022

10 noteworthy pharma leadership shake-ups this year

From GSK to Roche to Biogen, these were the most impactful executive changes at leading pharma companies in 2022.

By Karissa Waddick • Dec. 7, 2022

A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’

The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug. 

By Meagan Parrish • Dec. 6, 2022

Healthcare tech’s biggest busts

The metaverse, blockchain, DCTs and more — here are some of the most recent fails in healthcare tech.

By Taren Grom • Dec. 2, 2022

5 final FDA action dates to watch this year

A potential flurry of regulatory activity could be on the horizon yet this year — and several key drug approvals are at stake.

By Michael Gibney • Dec. 1, 2022